Sunday, November 8, 2026

EUR/CHF Over 3% Down In The Last 21 Sessions

EUR/CHF Over 3% Down In The Last 21 Sessions

(VIANEWS) - EUR/CHF (EURCHF) has been up by 3.75% for the last 21 sessions. At 16:06 EST on Sunday, 23 June, EUR/CHF (EURCHF) is $0.95.

EUR/CHF's yearly highs and lows, it's 5.725% up from its 52-week low and 3.857% down from its 52-week high.

Volatility

EUR/CHF's last week, last month's, and last quarter's current intraday variation average was a negative 0.11%, a negative 0.15%, and a positive 0.27%, respectively.

EUR/CHF's highest amplitude of average volatility was 0.37% (last week), 0.30% (last month), and 0.27% (last quarter), respectively.

Forex Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, EUR/CHF's Forex is considered to be oversold (<=20).

News about

  • Usd/jpy bulls turn cautious near 159.00, highest since April amid intervention fears. According to FXStreet on Friday, 21 June, "This results in the further widening of the US-Japan rate differential, which is seen as another factor weighing on the JPY and lending support to the USD/JPY pair. ", "The USD/JPY pair oscillates in a narrow range during the Asian session on Friday and consolidates its recent gains to the 159.00 neighborhood, or the highest level since late April touched the last hour. "
  • Usd/jpy price analysis: surges past 159.00, approaches yentervention levels. According to FXStreet on Friday, 21 June, "Despite that, the USD/JPY remains upward biased, and the next resistance would be 160.00. ", "The major has finally broken the barrier of 159.00 and closes to intervention levels reached on April 29, when the USD/JPY cleared the 160.00 figure. "

More news about EUR/CHF (EURCHF).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Season: Regulatory Deadlines and Data Readouts Against Cost Discipline and Slipping Timelines
From late October 2026 to January 2027, mid-cap biotechs cluster pivotal data presentations (ESMO, AHA, AASLD), FDA decision dates (ivonescimab BLA on 2026-11-14, lorundrostat on 2026-12-22) and Q3 earnings. Alongside these, several companies are managing capital: lowering R&D and SG&A guidance, pushing clinical milestones into 2027, authorizing a $400M buyback, and pursuing a delisting. Late-stage programs in oncology, hepatitis delta, hypertension and women's health look near commercial inflection, while cost cuts and delays point to uneven balance-sheet strength.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,996
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,996 facts checked against source5,552 source documents archived
Query this data → isubstrate.com